Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk… | Phase 1 / Phase 2 | terminated | May 10, 2019 | Zhejiang University | The study has gotten preliminary results and stopped advanced. | Other (stated, no rule matched) |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing…(NAC-PNP) | N/A | terminated | Mar 18, 2008 | Rijnstate Hospital | Unable to recruit enough patients | Enrollment / accrual |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | N/A | terminated | Nov 21, 2018 | NYU Langone Health | technical difficulties for scans on the research MRI system | Other (stated, no rule matched) |
| NCT04632199 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent… | Phase 1 | withdrawn | Nov 17, 2020 | Ipsen | Business decision not related to any safety or tolerability concern | Safety / toxicity |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | Phase 1 | terminated | Jun 25, 2019 | Eureka Therapeutics Inc. | Reallocation of resources to new HCC study. | Other (stated, no rule matched) |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive… | Phase 1 / Phase 2 | terminated | May 29, 2015 | Vanderbilt-Ingram Cancer Center | Interim analysis - toxicity | Safety / toxicity |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT01582009 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal… | Phase 1 / Phase 2 | terminated | Apr 20, 2012 | Roswell Park Cancer Institute | pts off study, PI left institute | Investigator |
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | withdrawn | Jan 17, 2013 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | Phase 2 | terminated | Mar 26, 2019 | Helix BioPharma Corporation | Study was halted at this time due to other budgetary priorities. Completion of reporting has been… | COVID-19 / pandemic |
| NCT04258592 | 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine… | Phase 1 | terminated | Feb 6, 2020 | Universitaire Ziekenhuizen KU Leuven | Insufficient recruitment | Enrollment / accrual |
| NCT03862066 | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer | — | terminated | Mar 5, 2019 | Medical University of South Carolina | Low accrual progress per internal scientific review committee | Enrollment / accrual |
| NCT02781506 | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell… | Phase 2 | terminated | May 24, 2016 | University of Texas Southwestern Medical Center | Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming… | Other (stated, no rule matched) |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | withdrawn | Apr 5, 2021 | University of Miami | Investigator Decision | Investigator |
| NCT04775056 | A Study to Evaluate Vaccines Against COVID-19 in the Real World | — | withdrawn | Mar 1, 2021 | Humanity & Health Medical Group Limited | No sponsor | Other (stated, no rule matched) |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | N/A | withdrawn | Apr 16, 2020 | Xoft, Inc. | Lack of site participation | Other (stated, no rule matched) |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | Phase 2 | withdrawn | Mar 2, 2022 | University of Oklahoma | PI left University | Investigator |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the… | Phase 2 / Phase 3 | terminated | Sep 17, 2018 | ERYtech Pharma | sponsor decision | Sponsor / business decision |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Phase 2 | withdrawn | Jun 28, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor withdrew funding | Funding |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | N/A | terminated | May 18, 2015 | Wright State University | Insufficient number of subjects meeting inclusion criteria | Other (stated, no rule matched) |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Oct 14, 2015 | Kathy Miller | Funder Decision | Other (stated, no rule matched) |
| NCT03720158 | Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of… | N/A | terminated | Oct 25, 2018 | Coordinación de Investigación en Salud, Mexico | The activities in the study hospital were seriously impacted by the medical care of COVID patients,… | COVID-19 / pandemic |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | Phase 2 | terminated | Sep 4, 2008 | BTG International Inc. | Study terminated prematurely by sponsor for business reason. One patient was enrolled. | Enrollment / accrual |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | — | withdrawn | Mar 13, 2020 | Beth Israel Deaconess Medical Center | Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected to… | COVID-19 / pandemic |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung… | Phase 1 / Phase 2 | terminated | Dec 24, 2019 | Ascentage Pharma Group Inc. | Sponsor decision | Sponsor / business decision |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or… | Phase 2 | terminated | Feb 2, 2017 | Nasser Hanna, M.D. | Funder decision - lack of accrual | Enrollment / accrual |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | Phase 2 | withdrawn | Feb 7, 2022 | MedSIR | Funder decided to not continue the study | Other (stated, no rule matched) |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | N/A | terminated | Jan 18, 2018 | Duke University | Lack of enrollment | Enrollment / accrual |
| NCT04849377 | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | Phase 2 | withdrawn | Apr 19, 2021 | Icahn School of Medicine at Mount Sinai | lack of eligible participants due to change in study criterias | Other (stated, no rule matched) |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | N/A | terminated | Jan 6, 2017 | University of Washington | Termination due to slow accrual | Enrollment / accrual |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With…(TOPAZ) | Phase 1 / Phase 2 | withdrawn | Aug 13, 2020 | Reva Basho | Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer. | Other (stated, no rule matched) |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Lion TCR Pte. Ltd. | Major changes in manufacturing process and investigational product | Drug supply |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC…(PATRON) | Phase 3 | terminated | Jul 26, 2011 | Cellxpert Biotechnology Corp. | Due to Interim Analysis and business concerns | Efficacy / futility |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in… | Phase 2 | terminated | Dec 13, 2007 | Boston Scientific Corporation | OncoGel did not show any impact on overall tumor response | Other (stated, no rule matched) |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab,… | Phase 2 | terminated | Feb 10, 2017 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | Phase 2 | terminated | Jul 19, 2016 | University of Alabama at Birmingham | Poor accrual | Enrollment / accrual |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | N/A | terminated | May 21, 2019 | Institut du Cancer de Montpellier - Val d'Aurelle | Change of the scientific and medical context that is no longer favorable to our study. This has… | Other (stated, no rule matched) |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by the IRB 5/26/22 due to non-compliance | Other (stated, no rule matched) |
| NCT04961320 | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell… | N/A | withdrawn | Jul 14, 2021 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With… | N/A | withdrawn | Feb 17, 2022 | City of Hope Medical Center | PI withdrawn | Other (stated, no rule matched) |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With… | Phase 2 | terminated | Mar 25, 2016 | University of Wisconsin, Madison | Study terminated early due to COVID-19 related slow enrollment and funding | COVID-19 / pandemic |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients… | Phase 2 | terminated | Mar 24, 2017 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast… | Phase 2 | withdrawn | Apr 17, 2020 | Academic and Community Cancer Research United | There are no patients enrolled on this study and all efforts are being discontinued | Enrollment / accrual |
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | — | withdrawn | Dec 9, 2019 | University Hospital, Grenoble | the possibility of obtaining histological data is too low due to the lack of availability of… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Aug 31, 2022source: clinicaltrials